An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
Cecilia Yeung’s research focuses on the molecular signatures of lymphomas, leukemias to guide diagnosis, treatment
Aug. 29, 2011
| By Colleen Steelquist
Dr. Cecilia Yeung, who wears dual hats as a hematopathologist and a molecular genetics pathologist, joined the faculty of the Pathology Labs in the Fred Hutchinson Cancer Research Center's Clinical Research Division this month.